StageZero Life Sciences Ltd SZLSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SZLSF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.03
- Day Range
- $0.03–0.03
- 52-Week Range
- $0.03–0.06
- Bid/Ask
- $0.01 / $0.04
- Market Cap
- $3.14 Mil
- Volume/Avg
- 640 / 77,307
Key Statistics
- Price/Earnings (Normalized)
- 0.02
- Price/Sales
- 1.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
Valuation
|
Metric
|
SZLSF
|
|---|---|
Price/Earnings (Normalized) | 0.02 |
Price/Book Value | — |
Price/Sales | 1.03 |
Price/Cash Flow | — |
Price/Earnings
SZLSF
Financial Strength
|
Metric
|
SZLSF
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.04 |
Interest Coverage | −37.52 |
Quick Ratio
SZLSF
Profitability
|
Metric
|
SZLSF
|
|---|---|
Return on Assets (Normalized) | −199.34% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SZLSF
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Csxywypsld | Mzsh | $209.3 Bil | |
DHR
| Danaher Corp | Cbmkggxqk | Ktpks | $174.8 Bil | |
IQV
| IQVIA Holdings Inc | Qxwbbnzv | Tnwvcw | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Jvbzgjfk | Rjshwn | $41.0 Bil | |
A
| Agilent Technologies Inc | Rsgbjsfh | Vvbl | $39.2 Bil | |
MTD
| Mettler-Toledo International Inc | Nllwyzmtj | Fwgvlp | $26.5 Bil | |
ICLR
| Icon PLC | Dxxhzmmp | Lnpvtz | $25.2 Bil | |
ILMN
| Illumina Inc | Mlmfkvx | Gttrt | $19.8 Bil | |
WAT
| Waters Corp | Rtktpqzl | Ptgz | $18.0 Bil | |
LH
| Laboratory Corp of America Holdings | Qdzxfqssp | Rlvkb | $17.1 Bil |